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Summary
Purpose:  To  determine  the effectiveness  of  three  different  combinations  for  the  ‘‘loading
phase’’ in  the  treatment  of  diabetic  macular  edema  (DME),  using  bevacizumab  (BVZ),  triamci-
nolone (TCL)  and subthreshold  macular  photocoagulation  (SMPC).
Methods:  Experimental,  longitudinal,  prospective,  comparative  and  blind.  Patients  were  ran-
domly assigned  to  three  treatment  branches:  Group  1:  BVZ  +  SMPC  (12  eyes),  Group  2:
SMPC + BVZ  +  TCL  (7  eyes),  Group  3:  BVZ  + TCL  (11  eyes).  Treatment  with  BVZ  and  TCL  was  given
every 4  weeks  for  3  months,  SMPC  was  applied  once at  the beginning  of  treatment.  Initial  and
final measurements  of  best  corrected  visual  acuity  (BCVA),  central  macular  thickness  (CMT)  and
intraocular  pressure  (IOP)  were  tested.
Results:  The  improvement  in  BCVA  and  the reduction  in  CMT  was  statistically  superior  in  group
of BVZ  + SMPCwhen  compared  to  the  other  groups.  There  were  no  differences  in  IOP.
Conclusions:  Combined  therapies  in the  ‘‘loading  phase’’are  a  good  option  when  treating  DME.
Although the  group  with  BVZ  +  SMPC  obtained  the  best results,  further  studies  with  longer  follow-
up and  a  higher  number  of participants  to  establish  this combined  therapy  as  the  first  treatment
option are  required.
© 2015  Universidad  Autónoma  de  Nuevo  León.  Published  by  Masson  Doyma
México S.A. This  is an  open  access  article  under  the CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Diabetic  macular  edema  (DME)  is  the main  cause  of
visual  loss  in patients  with  diabetic  retinopathy  (DR).  It is
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considered  to  be the  number  one cause  of blindness  at a
productive  age  in developed  countries.1--6 DME  is  the  result
of  alterations  of the inner  and  outer  blood-retinal  barri-
ers  (BRB)  due  to  the imbalance  between  the inflammatory
and  angiogenic  factors  of  the  retinal  pigment  epithelium
(PE)  and  the vitreoretinal  interface.  Among  these,  there  is
the  vascular  endothelial  growth  factor  (VEGF),  the hepato-
cyte  growth  factor  and  the interleukin  1B.  The  reduction
in  the pigment  epithelium-derived  anti-angiogenic  factor,
a potent  anti-inflammatory,  antioxidant  and  anti-angiogenic
http://dx.doi.org/10.1016/j.rmu.2015.05.007
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which  regulates,  among other  things,  VEGF  levels,  also  plays
an  important  role  in DME  pathophysiology.7--9 The  treatment
focuses  on  reestablishing  BRB, modulating  inflammatory  and
angiogenic  factors.  Among the current  options  to  accomplish
said  effect,  there  are the  thermal  laser  and  intravitreal  drug
therapies  (corticosteroids  and  anti-angiogenics).
The  laser  stimulates  the PE,  acting  as  a  substance  modu-
lator  for  PEDF  and  VEGF.  Moreover,  the thermal  destruction
of  the  outer  layers  of  the retina  reduces  the  metabolic
demand  and  oxygen  expenditure  with  the consequent  VEGF
reduction.10--18 Triamcinolone  is  the main  intraocular  corti-
costeroid  in the treatment  of  RD,  DME  and  other  neovascular
and  inflammatory  diseases  because  it inhibits  overregulation
of  inflammatory  molecules  and  VEGF.  Part  of  this regulation
was  completed  through  the reduction  of  vascular  permeabil-
ity  in  the  retina  by reducing  the liberation  of arachidonic
acid  derivatives,  such  as  prostaglandins.19--22 Bevacizumab
is  a  recombinant  humanized  monoclonal  antibody  (lgG1)
which  unifies  all isoforms  of  VEGF-A.  It was  approved  by  the
FDA  in  2004  for  metastatic  colon  cancer  treatment.  Since
then,  it  has  been  successfully  used  in an unofficial  man-
ner  to  treat  different  ocular  neovascular  illnesses,  such  as
age-associated  macular  degeneration,  proliferative  DR,  neo-
vascular  glaucoma,  premature  retinopathy,  macular  edema
secondary  to retinal  venous  obstruction  and  DME,  among
others.  Even  though,  to this  day,  it has not been  approved
by  the  FDA  nor  the  COFEPRIS  for  its ophthalmologic  use,
the  injection  of  1.25--2.5  mg in the  vitreous  cavity  has  been
performed  in a safe and effective  manner.23--29 Different
regimes  in  DME  treatment  have  been described.  The  laser
is  recommended  for  its application  in  a  selective  manner
and  on  a  single  occasion,  and,  if necessary,  reapply  it  in
intervals  of no  less  than  12  weeks  apart.18,30,31 Intravitreal
pharmacological  therapy  has  been  proposed  for  the  differ-
ent  ocular  neovascular  pathologies,  from  having  one  dose
and  repeating  treatment  as  deemed  appropriate  by  the
examiner  pro re  nata  (PRN),  up  to  a  monthly  dose  for 24
months,  without  regard  to  visual  and anatomic  changes.32--41
This  study  showed  that  the maximum  visual  and  anatomical
effect  occurs  during  the  first  three  doses,  and  those  fol-
lowing  them  only  helped  to  maintain  the inactivity  of  the
pathology;  thus,  the decision  in the selection  of  the scheme
during  this  ‘‘loading  stage’’  is fundamental.  The  ‘‘treat
and  observe’’  regime  is  currently  being  proposed.  This  is
to  apply  three  doses  in a row  with  an  interval  of  4  weeks
in  between  these  ‘‘loading  doses’’ until  accomplishing  the
maximum  visual  and  anatomic  effect,  repeating  the same
treatment  PRN.42 Based  on  the  possible  synergy  between
the  laser,  the corticosteroids  and  the anti-angiogenics,
the  combination  between  these has been  utilized  with
a  dual  intention;  to  accomplish  a  greater  visual  and
anatomic  effect,  and  to  accomplish  the  minimum  number
of  repetitions  in long-term  treatment  of  this chronic  degen-
erative  illness.35,36,43--49 In  spite  of  all  of  this,  the  question
about  which  combination  may  be  the  best  option remains
unanswered.
Objective
To  evaluate  effectiveness  with  three  different  treatment
combinations  in the ‘‘loading  phase’’  of  diabetic  macular
edema  (DME);  using bevacizumab  (BVZ),  triamcinolone  (TCL)
and  subthreshold  macular  photocoagulation  (SMPC).
Method  and materials
Controlled  clinical,  experimental,  prospective,  longitudi-
nal,  comparative  and  blind  essay,  including  those  patients
from  the  Department  of  Ophthalmology  at the ‘‘Dr.  José
Eleuterio  González’’  University  Hospital  using  the  follow-
ing inclusion  criteria:  male  and  female  with  diabetes  (type
I  or  II),  18  years  of  age  or  older,  with  a clinical  and  tomo-
graphic  DME  diagnosis,  best  corrected  visual  acuity  (BCVA)
higher  than  20/400.  Patients  who  did not present  any  of the
exclusion  criteria;  presence  of  significant  cataract  (accord-
ing to  the  researcher’s  criteria),  diagnosis  of  glaucoma,
vitreous  hemorrhage,  previous  intraocular  surgery,  macular
laser  treatment  and/or  intravitreal  drug  therapy  in  the  three
months  previous  to  the study. Patients  who  for  any  reason
did  not  complete  treatment  or  developed  complications  dur-
ing  treatment  were  eliminated.  The  protocol  was  evaluated
and  approved  by our  institution’s  Ethics  Committee  and  reg-
istered  under  the code  OF11-010.  The  study  was  conducted
following  the guidelines  established  in the Helsinki  Decla-
ration  and  the  International  Conference  on  Harmonization
Guidelines  for  Good  Clinical  Practices.  All  patients  signed
an  informed  consent  form  respecting  the  Official  Mexican
Standards  on  the  patients’  right  to  know  everything  about
their  illness  and  its possible  treatment  options.
Clinical  diagnosis  was  made  through  fundoscopy,  using
a  magnifying  glass  of  90  diopters  and  a Goldman  contact
lens  and  DME  was  considered  as  the central  thickening  of
at least a  diameter  of 1500  microns,  situating  the center
of  this  circle  in  the umbo foveolar.  Tomographic  diagnosis
was  performed  whenever  there  was  a  central  macular  thick-
ness  (CMT)  greater  than  230 microns  using  the ‘‘Macular
Thickness  Map’’  scanning  modality  of  the optical  coherence
tomography  (OCT)  using  Stratus  OCTTM by Carl  Zeiss.
Baseline  BCVA  measurements  were  taken  by  means  of dis-
tant  subjective  refraction  with  a Snellen  primer.  IOP  was
taken  by  means  of  an applanation  tonometry  from  Goldmann
and  clinical  and  OCT  findings  were  recorded.
Later,  the  randomized  selection  of  the  study  groups
was  made,  using  the six-sided  die technique:  numbers  1
or  4 to  group 1  (BVZ + SMPC),  numbers  2 or  5  to  group  2
(BVZ  + TCL + SMPC),  and  3  or  6 to  group  3 (BVZ  + TCL).  In  this
study,  the principal  investigator,  who  evaluated  the study
at the beginning  and  finalized  the treatment  regimen  dur-
ing the  ‘‘loading  phase’’,  did not  know  which group  each
patient  belonged  to.
The  laser  was  only applied  at the  beginning  of  treatment
(week  0),  with  the aim  of  avoiding  possible  complications
from  the  laser  threshold.  The  shots were made  on  sub-
threshold  (invisible)  mode,50 using  VISULASTM 532s  laser
equipment  (Carl  Zeiss  Meditec  AG.  Jena,  Germany).
The  pharmacological  treatment  was  performed  on  week
0, repeating  at weeks  4 and  8.  A dose of 1.25  mg in 0.05  ml
of  BVZ,  commercial  name  AvastinTM (Genentech  Inc.,  South
San  Francisco,  CA,  USA/Roche  Mexico)  was  applied  each
session.  The  TCL  utilized  was  ATLCTM (conservative-free),
distributed  by GRIN  laboratories,  Mexico,  at a  rate  of 2 mg
in 0.05  ml every  injection.  The  procedure  was  performed
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Table  1  Description  of  the studied  population.
N  Minimum  Maximum  Average  Standard  deviation
Age  30  48.00  71.00  58.6000  6.51576
Initial VA  30  0.20  1.30  0.6933  0.39994
Initial IOP  30  10.00  19.00  14.1667  2.52003
Initial CMT  30  297.00  732.00  396.9333  121.17469
Final IOP  30  11.00  18.00  14.7333  2.25806
Final VA  30  0.10  1.30  0.6133  0.38572
Final CMT  30  172.00  514.00  308.0333  80.62107
in  the  ‘‘cure  room,’’  with  prior  asepsis  and  antisepsis  of  the
eyelids  and  ocular  surface  with  a  solution  of povidone-iodine
at  5% (BetadineMR Alcon  Laboratories  Inc., Fort  Worth,  TX)
for  3 min  and  posterior  irrigation  with  a balanced  saline  solu-
tion.  The  topical  anesthesia  applied  was  tetracaine  (PontiTM
Laboratorios  Sophia,  S.A. de  C.V.,  Guadalajara,  Mexico).
The  injection  was  made  via pars  plana  in  the  superotem-
poral  quadrant  (4 mm from  the  corneal  limbo  in  phakic  eyes
and  3.5  mm  in pseudo-phakic  eyes).  A drop  of moxifloxacin
(VigamoxiTM, Alcon  Laboratories  Inc., Fort  Worth,  TX)  was
applied  as  a wide-spectrum  antibiotic  at the  end  of  the pro-
cedure,  which  was  used  prophylactically  at a rate  of  one
drop  every  6 h  for three  consecutive  days.
The  IOP,  BCVA,  clinical  findings  and  CMT  were  docu-
mented  on  week  12  after  the  beginning  of  treatment,  and
these  results  were compared  with  the  baseline  measure-
ments.  A  statistical  analysis was  made  by  the  IBM  SPSS
Statistics  software,  with  a  descriptive  analysis  of the  data,
which  was  compared  to  the average  through  the Student’s
t-test  for  related  samples.  p  < .05  was  determined  to  be  a
statistically  significant  difference.
Results
Our  study  included  30  eyes  from  30  patients,  with  ages
between  48 and 71  years  old, an initial  BCVA  of  .2 Log-
mar  (20/30)  to 1.3  Logmar  (20/400),  an initial CMT  average
of  396.93  m  and  an initial  average  IOP  of  14.16  mmHg
(Table  1).  The  global  BCVA  change  was  from  .6933  to  .6133
Logmar  (p  =  .24),  a  statistically  insignificant  difference.
The  global  CMT  change  was  from  396.93  m  to  308.03  m
(p  = .01),  a  statistically  significant  difference.  There  were
no  significant  differences  between  the  initial  and  final
IOP,  which  was  from  14.16  mmHg  to  14.77  mmHg  (p  = .176)
(Table  1).
In the  group  analysis,  we  found  that the  average  change
in  BCVA  in  group  1 (12  eyes,  BVZ  + SMPC)  was from  .64  to  .46
Logmar  (p  = .01),  a  statistically  significant  difference  com-
pared  to group  2 (7 eyes,  SPMC  +  BVZ  + TCL) which  was  from
.74  to .67  (p  =  .28)  and  group  3 (11  eyes,  BVZ  + TCL) which
was  from  .71  to  .73  (p  =  .67).
In  the  same  way,  the decrease  of  CMT  in group  1  was  from
456.5  m  to  319.41  m  (p = .019),  a  statistically  significant
value  in  comparison  to  group  2,  which  showed a  decrease
of  385.28  m to  290.57  m (p  =  .110), and  group  3, which
showed  a  decrease  of  339.36  m to  306.72  m  (p =  .110).
There  were  no  significant  differences  in IOP  change  in  any  of
the  3  groups  (Table  2). Two  patients  from  group  3  (BVZ  +  TCL)
and  one  from  group  2 (SPMC  + BVZ  +  TCL)  showed cataract
progression  which  required  surgery  more  than  IOL place-
ment.
Discussion
Since  the first  results  of ETDRS  were  published  in  1985, mac-
ular  laser  became,  and  still  is,  the ‘‘gold  standard’’  for
the  treatment  of  DME.18 Despite  this,  laser  offers  subop-
timal  results,  never  mind  the  possible  complications  due  to
the  burning  of  the external  retina.In  2008, Faghihi  et  al.36
demonstrated  that  a  single  dose  of  BVZ  or  BVZ  +  TCL  showed
superiority  in  diminishing  CMT  with  patients  with  DME  in
comparison  to  the  laser  alone.  Regardless,  the  effect  of
BVZ  on  monotherapy  was  short,  and  the decrease  of CMT
with  an  improvement  of  BCVA  only  correlated  the  BVZ  + TCL
group.36 In 2010,  Solaiman  et  al. compared  laser  and  BVZ
treatment  against  the monotherapy  of  either  one,  and  his
results  indicated  an improvement  in the BCVA  and  CMT  in  the
groups  that were  treated  with  BVZ  in combination  with  laser
as a  starting  therapy.48 In  2011,  DRCR.net  published  results
comparing  combined  therapy using  macular  lasers  and  BVZ
or  TCL. After  receiving  panphotocoagulation  laser  treat-
ment,  the visual  improvement  was  greater  in groups  that
received  BVZ  or  TCL, although  there  were  no  differences
in  muscular  thickness,  suggesting  that  combined  therapies
utilizing  laser  + BVZ  or  laser  +  TCL  were superior  to  laser
monotherapy.51 The  same  year,  Wang  et al.  demonstrated
the  beneficial  effects  of  BVZ  as  a monotherapy  or  in com-
bination  with  TCL  in the  treatment  of  DMC,  without  there
being  a  difference  between  the  two  groups.  In  2012, Soheil-
ian  et al.52 published  results  comparing  BVZ monotherapy,
BVZ  +  TCL  and  macular  laser  monotherapy.  The  group  with
the  laser  did not obtain  a significant  improvement  on  BCVA,
but  although  the  BCVA  improvement  in the BVZ  group  was
significant  during  the first  6 months, there  was  no  signifi-
cant  difference  between  the BVZ  group  and the combined
treatment  group  (BVZ  +  TCL)  at  the end  of the treatment.
Although  the CMT  reduction  was  greater  in the BVZ  group,
there  were  also  no  significant  differences  between  the 3
groups.52 To  our  knowledge  upon  the printing  of  this  publi-
cation,  the only  study  to utilize  a BVZ  + TCL  +  macular  laser
combined  triple therapy  was  published  by Chan  et al. in
2012,53 who  compared  the triple  therapy  to  laser  monother-
apy.  Regardless,  unlike  our study,  TCL  administration  was
subtenonian.  They  reported  an important  decrease  and  sus-
tained  CMT  in the  combined  therapy  group,  when compared
to  laser  monotherapy.53
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Table  2  Results  by  groups.
Group  Standard  deviation  Average  Difference  Value  of  p
BVZ  +  SPMC Initial/Final  BCVA 0.1959  0.175  0.5658  .010
Initial/Final CMT  173.60  137.08  50.1164  .019
Initial/Final IOP  0.79  −0.08333  0.2289  .723
BVZ +  TCL  +  SPMC Initial/Final  BCVA  0.1603  0.07143  0.6061  .283
Initial/Final CMT  133.87  94.71429  50.5996  .110
Initial/Final IOP  3.3594  −2.42857  1.2697  .104
BVZ +  TCL Initial/Final  BCVA  0.1401  −0.01818  0.0422  .676
Initial/Final CMT  61.63  32.63636  18.5836  .110
Initial/Final IOP 1.97  0.09091  0.5947  .882
The  majority  of  the reports  which  include  combined  ther-
apies  in  DME  demonstrate  the superiority  of any  one  of  them
over  laser  monotherapy,25,33,36,40,41,43,47--49,52,53 and  the small
impact  when  using  TCL.26,36,45--47,51--53 Our  results  indicate
that  the  BVZ  +  laser  combined  therapy  during  the ‘‘loading
phase’’  is  significantly  superior  to  therapies  that  included
TCL,  in  achieving  an BCVA  improvement  and  a  CMT  decrease,
and  we  suggest  that  this combination  be  repeated  PRN  in
long-term  follow-up.
One  possible  limitation,  owing  to  the methodological
design  of our  study  (which  did not  include  monotherapies)  is
that  we  could  not  conclude,  as  previous  publications  have,
if  the  combination  of  anti-angiogenic  +  laser  is  equal  to or
superior  than  monotherapy  with  anti-angiogenics.  Regard-
less,  this  was  not  the object  of  our study.  Another  of  the
limitations  of our  study  is  that  we  only  evaluated  the  ther-
apy  during  the  ‘‘loading  phase.’’  It  would be  interesting  to
follow-up  on  these  patients  in  the  long  term,  with  the  aim  of
determining  if this  therapeutic  combination  could  addition-
ally  be  effective  in prolonging  the  intervals  of the  retreats
in  the  long  term.
Conclusion
Our  study  shows  that  out of  the combined  therapies  during
the  ‘‘loading  phase’’  in DME  treatment,  the  combination  of
BVZ  and  SMPC  was  the best option.  However,  further  studies
are  necessary,  with  a longer  follow-up  period  and  a  larger
number  of participants,  to  establish  this alternative  as a  first
treatment  option.
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